About
HoneyBear Biosciences develops next-generation antibody-drug conjugates using its proprietary CoNectar® platform, which enables site-specific and dual-payload conjugation on therapeutic antibodies for global drug development.
Explore HoneyBear Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.